DOCSLIB.ORG

CATTARAUGUS COUNTY BOARD of HEALTH Publichea1th Prevent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CATTARAUGUS COUNTY BOARD of HEALTH Publichea1th Prevent CATTARAUGUS COUNTY BOARD OF HEALTH PublicHea1th Prevent. Promote. Protect. 1 Leo Moss Drive, Olean, NY 14760, Tel. (716) 373-8050, Fax (716) 701-3737 Established 1923 Andrew Klaczynski, MD, President Joseph Bohan, MD, Vice-President Giles Hamlin, MD Joseph Eade Sondra Fox, RN Richard Haberer James Lapey Georgina Paul, FNP MINUTES James Snyder August 1,2012 The 80ih meeting of the Cattaraugus County Board of Health was held at St. Bonaventure Clubhouse Restaurant, Route 417, Allegany, N ew York on August 1, 2012. The following members were present: Andrew Klaczynski, MD Richard Haberer Joseph Bohan, MD James Lapey Joseph Eade Georgina Paul, FNP Sondra Fox, RN James Snyder Also present were: Kevin D. Watkins, MD, MPH, Public Health Director Thomas Brady, County Attomey Paula Stockman, County Legislator Linda Edstrom, County Legislator Susan Labuhn, County Legislator Gilbert Witte, MD, Medical Director Karen Manners, Secretary to Public Health Director Henry Storch, MD, Clinic Physician Eric Wohlers, Environmental Health Director Raymond Jordan, Sr. Sanitarian Susan Andrews, Director of Patient Services Rick Miller, Olean Times Herald The meeting was called to order by Dr. Klaczynski. The roll was called and a quorum declared. Mr. Eade made a motion to approve the minutes of the June 6, 2012 Board of Health meeting. It was seconded by Dr. Bohan and unanimously approved. Director's Report: Dr. Watkins welcomed Dr. Storch to the meeting. Dr. Storch recently retired from the Olean Medical Group and has offered his expertise to the Health Department. He completed his residency at Charity Hospital in Louisiana and his cardiology fellowship at the University of Florida in Gainesville and served as the Chief Medical Officer in the Army in Oklahoma City, Oklahoma. He also had private practices in Jacksonville, Florida; Sanford, Maine; and Olean from 1986 until he retired this year. He is the recipient of multiple awards and it is a Cattaraugus County Board of Health Meeting August 1,2012 Page Two pleasure to have him at the Health Department. Dr. Watkins stated that the Health Department is applying for a Community Transformation Grant which will implement changes within our community to reduce childhood obesity. Obesity among children and adolescents has tripled over the past three decades and currently a third of children in New York are obese/overweight. This grant is sponsored by the Centers for Disease Control and Prevention (CDC). New York State Department of Health will be the lead applicant and Cattaraugus County Health Department along with Chautauqua and Broome County Health Departments have been asked by the State to participate in this joint application process. The changes that will be implemented will be to increase physical activity in early child care and school settings, increase early child care center nutritional programs, restrict the sale of sugar sweetened beverages in schools and municipal buildings, restrict the use of tobacco products at school events that are not on school grounds, and to reduce the exposure to second hand smoke in multi-unit housing settings. The schools that have been identified to participate in this grant are Salamanca, Gowanda and the Olean school districts. The two-year grant is for $500,000 and we will involve the participation of our municipalities, the school superintendents and the community as well. This is a positive initiative to implement changes that we need to see within our community. Dr. Watkins stated that we continue to monitor the outbreak of Whooping Cough (Pertussis). As of 7119112 there have been 18,000 cases reported in the United States this year which is more than twice as many as last year. According to the CDC if it continues at this rate, the outbreak will be worse than in 1959 where there were more than 40,000 cases ofWhooping Cough. In New York State, the number of cases has increased to approximately 1,217 so far and the incidence of Pertussis in New York State outside of New York City is about 11 per every 100,000 individuals, but the national incidence is about 5 per every 100,000 individuals. There have been no deaths in New York State secondary to Pertussis so far this year. We continue to be vigilant and warn our residents ofthe need to get a Tdap booster. The hospital has been working with us to assure that all mothers that have recently delivered are offered the vaccine. We have had two confirmed cases and two probable cases within Cattaraugus County this year. All ofthose cases have been treated and families have received the appropriate prophylaxis. We are working with the State to see if these vaccines can be made available at no cost to the public but at this particular time there has been no movement by the State on that effort. Today in the Journal of American Medical Association there was an interesting article (enclosed). stating that the nwnber ofindividuals that are part ofthis epidemic ofWhooping Cough is secondary to the type ofvaccine that is currently being used. The acellular pertussis vaccine, which is currently being used may not have the same effective immune response as when the whole cellular pertussis vaccine was being used. The vaccine was switched in the 1990's and that is when the epidemic seems to have began to flourish around 2000 or so when there was an increase in Whooping Cough. Their study shows that ifwe switch back to the whole cellular Pertussis vaccine we will probably not see the high nwnber of individuals redeveloping or coming down with Whooping Cough. The treatment for Pertussis has not changed at all, we continue to treat those individuals with the macrolide agents such as Azithromycin, Clarithromycin or Erythromycin and if they are allergic to any ofthose, then they are given Bactrium as an alternative. Children are still vaccinated at 2,4, Cattaraugus County Board of Health Meeting August 1,2012 Page Three and 6 months of age, at 15-18 months of age and between 4 - 6 years of age as well. Dr. Watkins reported that we continue to watch the public health and health planning council minutes and agendas to monitor the approval ofhome health agencies that have applied to expand or become certified home health agencies. Their last meeting was on July 26,2012 and there were several applications for the Certified Home Health Agency licensure expansion on their agenda for upstate and downstate New York. There was one application for review from our area; however the panel denied their request to expand into our area, which leaves four other applicants whose decision is still pending by this particular board. We will continue to update the Board on future outcomes. Dr. Watkins also reported that on July 25, 2012 the County Legislature overwhelming supported a resolution to encourage the State legislators to pass a State law to ban the manufacture, distribution, sale and possession ofdangerous, unregulated synthetic drugs like bath salts. These designer drugs are specifically synthesized with a similar modified structure ofa Schedule 1 controlled substance in order to avoid existing drug laws and can be continually chemically modified to avoid legal repercussions while maintaining their intended effects and usages. That schedule one controlled substance is amphetamine. The resolution urges the State Legislators to prohibit the use of cathinones; the parent compound for the designer drug bath salts. Amphetamines and cathinones are very similar in structure, adding methyl groups or non-metals (i.e. fluorine) to the cathinones allow manufacturers to get around the current order, which list the components ofthe drugs. Bath salts are frequently made up ofone ofseveral types ofdesigner drugs. Mephedrone, methylone and Methylenedioxyprovalerone are the three most popular types ofbath salts. Dr. Watkins handed out a copy ofthe chemical structures. Bath salts stimulate the body's central nervous and has similar effects to cocaine and amphetamines. Dr. Watkins stated that some of the side affects of the synthetic drugs include increased heart rate and blood pressure, hallucinations, paranoia, suicidal thoughts, violent behavior, nausea and vomiting. In Cattaraugus County the sale or production of this product is prohibited, but there should be a nationwide law that would ban the sale and use of synthetic drugs. Dr. Watkins stated that there was discussion at the last meeting regarding the Clean Indoor Air Act waivers for establishments that will be requesting renewals at the end of the year. At that time, Dr. Bohan requested information on how long each establishment has had a waiver to determine ifthese establishments have recouped their investments that they made (building a separate area to accommodate smokers in their establishments) in order to be in compliance with the regulations that granted them the waiver. Dr. Watkins handed out a copy of that information. Mr. Eade made a motion to move into Executive Session to seek advice from Mr. Brady, County Attorney. It was seconded by Dr. Bohan and unanimously approved. After moving out ofExecutive Session, it was noted that no actions were taken; advice was obtained from Mr. Brady, County Attorney. Mr. Snyder explained that the Board has discussed the Clean Indoor Air Act waivers several times in the past and he feels that currently there is 99.9% compliance with the Clean Indoor Air Act from establishments. He believes ifthese establishments are not granted waivers they will go out ofbusiness. Dr. Bohan asked ifwe can get information from Cattaraugus County Board of Health Meeting August 1,2012 Page Four other counties on whether they have had any legal issues when disapproving waivers, whether they have been successful in discontinuing waivers and if other Off Track Betting (OTB) offices allow smoking before any decisions are made. Mr. Brady agreed to do the legal research to answer that question.
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • Mephedrone Is a Class B Drug, Which Means Self-Referral Form and It Is Illegal to Possess, Sell Or Give Away
    THE LAW CONTACT INFORMATION Novel Psychoacve Substances (NPS) are If you would like support controlled substances under the Misuse of around your substance HMP BRISTOL Drugs Act (1971). use, please complete a Substance Misuse Team Mephedrone is a Class B drug, which means self-referral form and it is illegal to possess, sell or give away. return to Health Care. Possession can result in prosecuon and up PALS to a five year prison sentence or an unlimited fine. To make a comment, raise a concern Mephedrone or make a complaint, please contact the Trust’s Paent Advice and Liaison Supplying someone else, even your friends, Service (PALS). can result in a prison sentence of up to 14 Know the effects years or an unlimited fine. Tel: 01249 468261 Freephone: 0800 073 1778 Email: [email protected] Being convicted of a drug‐related offence could have a serious impact on your future. This could affect the types of jobs you apply for and stop you from entering certain OTHER FORMATS OR countries. LANGUAGES If you need this informaon in other formats (such as large print, Braille) or in another language, please call PALS Lead: Chris Eade Leaflet code: 326 Approval date: Aug 2014 Review due: Aug 2017 WHAT IS MEPHEDRONE EFFECTS THE RISKS Mephedrone is also known as The effects of mephedrone can vary and All drugs pose a risk of dependency and meow meow, meph, m‐cat and miaow can affect people differently. It is never can cause short and long‐term damage certain what effect it will have on the user.
    [Show full text]
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • 3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • 10.30.19 Didactic
    STIMULANTS PART II Michael H. Baumann, Ph.D. Designer Drug Research Unit (DDRU), Intramural Research Program, NIDA, NIH Baltimore, MD 21224 Chronology of Stimulant Misuse 1. 2000s: Methamphetamine 2. 2010s: Bath Salts 3. Summary 2 Topics Covered for Each Substance Chemistry Formulations and Methods of Use Pharmacokinetics and Metabolism Desired and Adverse Effects Chronic and Withdrawal Effects Neurobiology Treatments 2000s: Methamphetamine Methamphetamine, a synthetic stimulant 5 Formulations and Methods of Use Methamphetamine (i.e., Ice or Crystal) Smoking using pipes Methamphetamine HCl Intravenous injection of solutions using needle and syringe Intranasal snorting of crystals Pharmacokinetics and Metabolism Pharmacokinetics Smoked and intravenous drugs reach brain within seconds Intranasal drug reaches brain within minutes Much longer half-life than cocaine Metabolism N-demethylation to form amphetamine (bioactive) Hydroxylation to form inactive metabolites Desired Effects Enhanced Mood and Euphoria Increased Attention and Alertness Decreased Need for Sleep Appetite Suppression Sexual Arousal Adverse Effects Psychosis Arrhythmias, Palpitations, Heart Attack Hypertension, Stroke Hyperthermia, Rhabdomyolysis Multisystem Organ Failure 11 www.facesofmeth.us. “METH Mouth” 12 Molecular Sites of Action SLC6 Monoamine Transporters Dopamine transporter (DAT) Norepinephrine transporter (NET) 5-HT transporter (SERT) Other sites Vesicular Monoamine Transporter 2 (VMAT2) Trace amine-associated receptors (TAAR1)
    [Show full text]
  • Effects of Mephedrone and Amphetamine Exposure During Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis
    International Journal of Molecular Sciences Article Effects of Mephedrone and Amphetamine Exposure during Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis Pawel Grochecki 1, Irena Smaga 2 , Malgorzata Lopatynska-Mazurek 1, Ewa Gibula-Tarlowska 1, Ewa Kedzierska 1, Joanna Listos 1, Sylwia Talarek 1, Marta Marszalek-Grabska 3 , Magdalena Hubalewska-Mazgaj 2, Agnieszka Korga-Plewko 4 , Jaroslaw Dudka 5, Zbigniew Marzec 6, Małgorzata Filip 2 and Jolanta H. Kotlinska 1,* 1 Department of Pharmacology and Pharmacodynamics, Medical University, 20-093 Lublin, Poland; [email protected] (P.G.); [email protected] (M.L.-M.); [email protected] (E.G.-T.); [email protected] (E.K.); [email protected] (J.L.); [email protected] (S.T.) 2 Department of Drug Addiction Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland; [email protected] (I.S.); [email protected] (M.H.-M.); mal.fi[email protected] (M.F.) 3 Department of Experimental and Clinical Pharmacology, Medical University, 20-090 Lublin, Poland; [email protected] 4 Independent Medical Biology Unit, Medical University, 20-090 Lublin, Poland; [email protected] 5 Department of Toxicology, Medical University, 20-090 Lublin, Poland; [email protected] 6 Department of Food and Nutrition, Medical University, 20-093 Lublin, Poland; [email protected] Citation: Grochecki, P.; Smaga, I.; * Correspondence: [email protected] Lopatynska-Mazurek, M.; Gibula-Tarlowska, E.; Kedzierska, E.; Abstract: A synthetic cathinone, mephedrone is widely abused by adolescents and young adults. Listos, J.; Talarek, S.; Despite its widespread use, little is known regarding its long-term effects on cognitive function.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Written Witness Statement for U.S. Sentencing Commission's Public
    STATEMENT OF TERRENCE L. BOOS, PH.D. SECTION CHIEF DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION and CASSANDRA PRIOLEAU, PH.D. DRUG SCIENCE SPECIALIST DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION - - - BEFORE THE UNITED STATES SENTENCING COMMISSION - - - HEARING ON SENTENCING POLICY FOR SYNTHETIC DRUGS - - - OCTOBER 4, 2017 WASHINGTON, D.C. 1 Introduction New Psychoactive Substances (NPS) are substances trafficked as alternatives to well- studied controlled substances of abuse. NPS have demonstrated adverse health effects such as paranoia, psychosis, and seizures to name a few. Cathinones, cannabinoids, and fentanyl-related substances are the most common NPS drug classes encountered on the illicit drug market, all with negative consequences for the user to include serious injury and death. Our early experience saw substances being introduced from past research efforts in an attempt to evade controls. This has evolved to NPS manufacturers structurally altering substances at a rapid pace with unknown outcomes to targeting specific user populations. These substances represent an unprecedented level of diversity and consequences. Due to clandestine manufacture and unscrupulous trafficking, the user is at great risk. A misconception exists that these substances carry a lower risk of harm In reality, published reports from law enforcement, emergency room physicians and scientists, accompanied with autopsies from medical examiners, have clearly demonstrated the harmful and potentially deadly consequences of using synthetic cathinones. These substances are introduced in an attempt to circumvent drug controls and the recent flood of NPS remains a challenge for law enforcement and public health. The United Nations Office on Drugs and Crime reported over 700 NPS encountered.1 The manufacturers and traffickers make minor changes in the chemical structure of known substances of abuse and maintain the pharmacological effect.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • 'Bath Salts' Constituents MDPV, Mephedrone, and Methylone Serena Allen East Tennessee State University
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works 5-2018 The ombinedC Neuropharmacology and Toxicology of Major 'Bath Salts' Constituents MDPV, Mephedrone, and Methylone Serena Allen East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Medicinal Chemistry and Pharmaceutics Commons, Neuroscience and Neurobiology Commons, Pharmacology Commons, Pharmacy and Pharmaceutical Sciences Commons, and the Toxicology Commons Recommended Citation Allen, Serena, "The ombC ined Neuropharmacology and Toxicology of Major 'Bath Salts' Constituents MDPV, Mephedrone, and Methylone" (2018). Electronic Theses and Dissertations. Paper 3431. https://dc.etsu.edu/etd/3431 This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. The Combined Neuropharmacology and Toxicology of Major ‘Bath Salts’ Constituents MDPV, Mephedrone, and Methylone A dissertation presented to the faculty of the Department of Biomedical Sciences East Tennessee State University In partial fulfillment of the requirements for the degree Doctor of Philosophy in Biomedical Sciences, Pharmaceutical Science Concentration by Serena A. Allen May 2018 Dr. Brooks Pond,
    [Show full text]